Abstract:A series of ruthenium(II) complexes containing andrographolide‐based hydrazide derivatives were synthesized and characterized. The anticancer nature of the synthesized compounds has examined with MTT assay, staining assays, and flow cytometry analysis. All the ligands and complexes showed potent anticancer activity. A new set of andrographolide‐appended hydrazide derivatives (AFC, AGC, and ATC) were prepared from the reaction of andrographolide with furan‐2‐carboxylic acid hydrazide (AFC), pyridine‐3‐carboxylic acid hydrazide (AGC), and thiophene 2‐carboxylic acid hydrazide (ATC), and their corresponding ruthenium(II) complexes (Ru‐AFC, Ru‐AGC, and Ru‐ATC) were synthesized by the direct reaction of [RuCl2(η6‐p‐cymene)]2 with ligands in dichloromethane under stirring condition. The compounds were analyzed by elemental analysis, IR, UV‐Vis, 1H NMR, and ESI‐MS spectrometric techniques, and the obtained spectral data revealed that the ligands coordinated to Ru(II) ion through their enone oxygen and amine nitrogen. Antioxidant activities of the ligands and complexes were calculated against DPPH•, ABTS•+, O2−, and NO• free radicals and their results were compared with standard antioxidants. The cytotoxic activity of the synthesized ligands and complexes toward A549 and HeLa cell lines was evaluated using MTT method (MTT = 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide). Among the compounds, the complex Ru‐AGC showed better cytotoxic effect against A549 and HeLa cancer cells with IC50 values of 4.75 ± 0.17 and 6.32 ± 0.26 μM, respectively. Further, the nontoxic nature of the compounds was confirmed by using human umbilical vein endothelial (HUVEC) cells. The apoptosis was inspected with AO/EB and DAPI staining methods; further, the percentages of the apoptotic and necrotic cells were determined by flow cytometry. Overall, the biological activities of our ruthenium(II)‐arene complexes were found to be more potent than their parent ligands due to chelation, and among the complexes, Ru‐AGC showed better activity due to the presence of pyridine ring in the N‐terminal position of the ligand. The obtained results highlighted the strong possibility to develop highly active ruthenium complexes as anticancer agents.

Promoting the Anticancer Activity with Multidentate Furan-2-Carboxamide Functionalized Aroyl Thiourea Chelation in Binuclear Half-Sandwich Ruthenium(II) Complexes

Dinuclear arene ruthenium(II) arylthiourea complexes: Synthesis, structure, cancer cell growth inhibition and apoptosis induction studies

Synthesis, characterization, and anticancer activity of dithiocarbamate ruthenium(II) complexes

Analysis of antiproliferative activity of new half-sandwich arene Ru(II) thiophene based aroylhydrazone complexes

Half-Sandwich Arene Ruthenium(II) Thiosemicarbazone Complexes: Evaluation of Anticancer Effect on Primary and Metastatic Ovarian Cancer Cell Lines

Half-Sandwich Iridium(III), Rhodium(III), and Ruthenium(II) Complexes Chelating Hybrid sp 2 -N/sp 3 -N Donor Ligands to Achieve Improved Anticancer Selectivity

New Organoruthenium(II) Complexes Containing Andrographolide‐Appended Hydrazide Derivatives: Synthesis, Spectral Characterization, Anticancer Evaluation

THE SYNTHESIS AND CHARACTERIZATION OF DINUCLEAR PLATINUM COMPLEXES BRIDGED BY DIPYRIDYL SELENIDES OR SULFIDES

Biomolecular Interactions and Anticancer Mechanisms of Ru(II)-Arene Complexes of Cinnamaldehyde-Derived Thiosemicarbazone Ligands: Analysis Combining In Silico and In Vitro Approaches

Ligand-Based Neutral Ruthenium(Ii) Arene Complex: Selective Anticancer Action

Potent Half-Sandwich 16-/18-Electron Iridium(III) and Ruthenium(II) Anticancer Complexes with Readily Available Amine-Imine Ligands

Anticancer Study on Ir III and Rh III Half-Sandwich Complexes with the Bipyridylsulfonamide Ligand

Synthesis, characterization, and anticancer activity of Ru( p -cymene) complexes bearing pyrazolyl–pyridine type ligands

Addition of Ethynylferrocene to Transition-Metal Complexes Containing a Chelating 1,2-Dicarba-closo-dodecaborane-1,2-dichalcogenolate Ligand--in Vitro Cooperativity of a Ruthenium Compound on Cellular Uptake of an Anticancer Drug.

Anticancer application of half-sandwich iridium(III) ferrocene-thiosemicarbazide Schiff base complexes

Bifunctional Ruthenium(ii) Polypyridyl Complexes of Curcumin As Potential Anticancer Agents

Synthesis of Novel Cu(II), Co(II), Fe(II), and Ni(II) Hydrazone Metal Complexes as Potent Anticancer Agents: Spectroscopic, DFT, Molecular Docking, and MD Simulation Studies

Novel thiosemicarbazone complexes as anticancer agents: Synthesis, characterization, cytotoxicity, docking, and density functional theory studies

Toward the Design of Novel Polynuclear Platinum Antitumor Complexes: a Polydentate Ligand System Based on Dipyridylamine and 1,3,5-Trimethylenebenzene.

Fortuitous synthesis of unsaturated half-sandwich Ruthenium(II) complexes via solvent-involved rearrangement and their biological evaluation

Anticancer and antimicrobial properties of novel η6- p-cymene ruthenium(ii) complexes containing a N,S-type ligand, their structural and theoretical characterization